Bill Miller’s Biogen BIIB Stock Holding History

Bill Miller’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-79,493	Closed	-$27.5M	–	128
2021 Q2	$27.5M	Buy	+79,493	New	+$24.1M	0.66%	43

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bill Miller's BIIB Position: Q3 2021 in Review

Bill Miller sold out of Biogen (BIIB) in Q3 2021, closing a stake of 79,493 shares — an estimated $27.5M sold.

Bill Miller first reported a position in BIIB in Q2 2021 and held it in 1 quarter. The position peaked at $27.5M in Q2 2021. 1,040 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

Bill Miller reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
Bill Miller sold 79,493 Biogen shares in Q3 2021, an estimated $27.5M.
Bill Miller first reported a position in Biogen in Q2 2021 and held it in 1 quarter.
Bill Miller's Biogen position peaked at $27.5M in Q2 2021.
1,040 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on Miller Value Partners's 13F filing for Q3 2021, filed 15 Nov 2021.